期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 82, 期 1, 页码 65-69出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2015.02.003
关键词
beta-Lactamase; Avibactam; ESBL; Carbapenemase; Inhibitor-resistance
资金
- AstraZeneca Pharmaceuticals
- Actavis
- Medical Scientist Training Program Training Grant, Case Western Reserve University [T32 GM07250]
- Cleveland Department of Veterans Affairs
- Veterans Affairs Career Development Award
- Department of Veterans Affairs Merit Review Program [1I01BX001974]
- Veterans Integrated Service Network 10 Geriatric Research, Education, and Clinical Center (VISN 10 GRECC)
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01 AI100560, R01 AI063517]
Avibactam is a novel beta-lactamase inhibitor that restores the activity of otherwise hydrolyzed beta-lactams against Gram-negative bacteria expressing different classes of serine beta-lactamases. In the last decade, beta-lactam-avibactam combinations were tested against a variety of clinical isolates expressing multiple commonly encountered beta-lactamases. Here, we analyzed isogenic Escherichia coli strains expressing selected single beta-lactamase genes that were not previously tested or were not characterized in an isogenic background. The activities of ceftazidime, ceftaroline, and aztreonam alone and in combination with 4 mg/L of avibactam, as well as comparator agents, were assessed against a unique collection of isogenic strains of Escherichia coli carrying selected extended-spectrum, inhibitor-resistant, and/or carbapenem-hydrolyzing bla genes. When combined with avibactam, ceftazidime, ceftaroline, or aztreonam MICs were reduced for 91.4%, 80.0%, and 80.0% of isolates, respectively. The data presented add to our understanding of the microbiologic spectrum of these beta-lactams with avibactam and serve as a reference for further studies. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据